ATyr Pharma, Inc.: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei aTyr Pharma, Inc. listata cu simbolurile US.ATYR, US.LIFE ==Descriere companie== aTyr Pharma Inc (www.atyrpharma.com) is a biotechnology company. The Company’s programs include ATYR1923, ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. It is developing ATYR1923 as a disease-modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need, which include interstitial lung disease (ILD), a group of rare immune-mediated disord...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
aTyr Pharma Inc (www.atyrpharma.com) is a biotechnology company. The Company’s programs include ATYR1923, ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. It is developing ATYR1923 as a disease-modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need, which include interstitial lung disease (ILD), a group of rare immune-mediated disorders that can cause progressive fibrosis of the lung. ATYR2810, is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands, VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive solid tumors where NRP2 is implicated. The Company is also advancing its preclinical pipeline of tRNA synthetases and NRP2 targeting antibodies through internal research efforts and academic collaborations. | aTyr Pharma Inc (www.atyrpharma.com) is a biotechnology company. The Company’s programs include ATYR1923, ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. It is developing ATYR1923 as a disease-modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need, which include interstitial lung disease (ILD), a group of rare immune-mediated disorders that can cause progressive fibrosis of the lung. ATYR2810, is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and [[one]] of its primary ligands, VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive solid tumors where NRP2 is implicated. The Company is also advancing its preclinical pipeline of tRNA synthetases and NRP2 targeting antibodies through internal research efforts and academic collaborations. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||